Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) has announced the appointment of Eran Kuratz as head of supply chain and business process administration for its wholly owned subsidiary, Scinai Biopharma Services Ltd. This strategic hire comes as the company expands its contract development and manufacturing organization (CDMO) platform, positioning itself to meet growing demand for biologics and small-molecule manufacturing services.
Kuratz brings over 30 years of leadership experience in supply chain and operations across the pharmaceutical, biotechnology, medical-device, and industrial sectors. In his new role, he will oversee critical functions including procurement, contracting, inventory management, logistics, budgeting, IT and business systems, cybersecurity, and cross-functional business processes. His appointment is expected to enhance operational efficiency and support the company's growth trajectory.
The move follows Scinai's acquisition of Recipharm Israel, which was completed in the first quarter of 2026. This acquisition added a second development and manufacturing site in Yavne, complementing the company's existing operations in Jerusalem. Together, these facilities provide a comprehensive range of capabilities, including biologics process development, aseptic manufacturing, sterile fill-and-finish, small-molecule active pharmaceutical ingredient (API) development and synthesis, analytical-method development, and Good Manufacturing Practice (GMP) manufacturing.
With the integration of the Yavne site, Scinai's CDMO platform is now better equipped to serve a diverse clientele, from biotech startups to established pharmaceutical companies. The expanded capacity and expertise are crucial as the global CDMO market continues to grow, driven by increasing outsourcing of manufacturing by drug developers. According to industry reports, the CDMO market is projected to reach significant valuations by 2030, and Scinai aims to capture a share of this market by offering high-quality services.
Scinai Immunotherapeutics is a biopharmaceutical company focused on developing innovative immunology therapies. Its pipeline includes therapeutic candidates licensed from the Max Planck Society and PinCell S.r.l. The company's dual focus on drug development and CDMO services allows it to leverage its manufacturing expertise to generate revenue while advancing its own research programs. This strategic approach is designed to create shareholder value by diversifying income streams and reducing reliance on external funding for its pipeline.
Investors and industry watchers will likely view this appointment as a positive step toward strengthening the company's operational capabilities. By bringing in a seasoned professional like Kuratz, Scinai demonstrates its commitment to maintaining high standards in supply chain management and business processes, which are critical for regulatory compliance and customer satisfaction. As the CDMO platform expands, effective supply chain management will be essential to ensure timely delivery of materials and services.
The company's newsroom provides updates on these developments and other corporate announcements. For more information about Scinai Immunotherapeutics and its CDMO services, interested parties can visit the company's newsroom at https://ibn.fm/SCNI.
